Lifecore Biomedical, Inc. De (LFCR) Non Operating Interest Expenses (2010 - 2025)

Lifecore Biomedical has reported Non Operating Interest Expenses for 16 years, with the latest figure at $9.9 million in Q2 2025.

• On a quarterly basis, Non Operating Interest Expenses rose 100.81% year-over-year to $9.9 million in Q2 2025; TTM through May 2025 was $23.7 million, a 61.77% increase from a year earlier, with the FY2024 full-year figure at $14.7 million, down 16.92% from the prior year.
• Non Operating Interest Expenses was $9.9 million for Q2 2025 at Lifecore Biomedical, up from $4.8 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $9.9 million in Q2 2025, with the low at $1.7 million in Q2 2022.
• Average Non Operating Interest Expenses over 5 years is $4.1 million, with a median of $3.6 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2022: Non Operating Interest Expenses jumped 268.17% in 2021, then tumbled 47.05% in 2022.
• Over 5 years, Non Operating Interest Expenses stood at $2.8 million in 2021, then jumped by 30.97% to $3.6 million in 2022, then declined by 10.57% to $3.2 million in 2023, then soared by 42.64% to $4.6 million in 2024, then surged by 113.19% to $9.9 million in 2025.
• The last three Non Operating Interest Expenses figures came in at $9.9 million (Q2 2025), $4.8 million (Q1 2025), and $4.6 million (Q4 2024), per Business Quant data.